Top Tweets for #nmHSPC
Macroscopic local relapse after RP in the context of high-risk #nmHSPC. Presentation by @PCaParker @royalmarsdenNHS. #EAU26 written coverage by @RKSayyid @UAUrology > https://t.co/ogdFusOcGv @Uroweb
🚩Do not miss these #CUA24 Educational Sessions featuring Brita Danielson, @UroOncMD, Christian Kollmannsberger, @wayne_brisbane, Bobby Shayegan, Hanmu Yan. 🚩Reserve your spot today >>> https://t.co/cMHALbepR4
#nmHSPC #prostatecancer #AI
🚩Do not miss these #CUA24 Educational Sessions featuring Brita Danielson, @UroOncMD, Christian Kollmannsberger, @wayne_brisbane, Bobby Shayegan, Hanmu Yan. 🚩Reserve your spot today >>> https://t.co/cMHALbdS1w
#nmHSPC #prostatecancer #AI
Global QOL was not meaningfully impacted by enzalutamide suspension in in patients with biochemically recurrent #nmHSPC responding well to enzalutamide, according to a data from the phase 3 EMBARK trial presented at #ASCO24. @SFreedlandMD @CSCancerCenter
https://t.co/FGnZyJ6K0g
The #ROAR study showed that #rucaparib had an acceptable safety & efficacy profile as an ADT-sparing approach in pts w/ high-risk biochemically recurrent #nmHSPC w/ #BRCA 1/2 or other homologous recombination repair mutations. @neerajaiims @maughanonc https://t.co/gtVZyJYzE5
経口アンドロゲン受容体阻害薬 #エンザルタミド について、生化学的再発のリスクが高い #非転移性去勢感受性前立腺がん（#nmCSPC、#nmHSPC）への適応拡大が米国で承認されました。
https://t.co/rXafTLL96A
Enzalutamide + leuprolide showed promise in patients with #nmHSPC with high-risk biochemical recurrence vs leuprolide alone, according to findings from the phase 3 EMBARK trial. #pcsm | @Dan_Theodorescu @CedarsSinaiMed
https://t.co/IzinhThhW8
#EMBARK: Health-related quality of life in #nmHSPC patients with high-risk BCR. Presentation by @SFreedlandMD @CedarsSinai. #ESMO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/Mu8gK3NFq1 @myESMO
PSMA PET findings in an “EMBARK-like” cohort of pts with high-risk #nmHSPC: a single center posthoc retrospective analysis. Presented by Wesley Armstrong @uclacaltechmstp. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/39xOmo58zi @ASCO
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/YlufsDI3mW @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/lqQhrMyWRM @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/YlufsDIBcu @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK study: A phase 3 randomized study of enzalutamide + leuprolide and enzalutamide monotherapy in HR #nmHSPC with rising PSA after local therapy @SFreedlandMD @CSCancerCare. #WatchNow > https://t.co/19ihyEoaWJ @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/lqQhrMQxJk @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK study: A phase 3 randomized study of enzalutamide + leuprolide and enzalutamide monotherapy in HR #nmHSPC with rising PSA after local therapy @SFreedlandMD @CSCancerCare. #WatchNow > https://t.co/19ihyEFLOh @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/YlufsDI3mW @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK study: A phase 3 randomized study of enzalutamide + leuprolide and enzalutamide monotherapy in HR #nmHSPC with rising PSA after local therapy @SFreedlandMD @CSCancerCare. #WatchNow > https://t.co/19ihyEoaWJ @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/lqQhrMzuHk @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
Last Seen Hashtags on Sotwe
ميقا_حصريات
izmittravesti
Seen from Turkey
transfemjax
Seen from United States
xlii or #exny or #nolimit() #momson() +filter:native_video
Seen from Peru
AAOncheck
Seen from United States
azginüniversiteli
Seen from Turkey
นัดเยสสาวใหญ่
Seen from Thailand
หีเมียทางบ้าน
Seen from Thailand
Chinesemom
Seen from Malaysia
سالب_جده_موجب_جده_مبادل_جده
Most Popular Users
Elon Musk 
@elonmusk
240.6M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.6M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.7M followers
Taylor Swift
@taylorswift13
81.5M followers
Lady Gaga
@ladygaga
73.1M followers
Virat Kohli
@imvkohli
69.9M followers
Kim Kardashian
@kimkardashian
69.8M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.9M followers
Neymar Jr
@neymarjr
62.7M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.8M followers